CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
Congratulations to Dr. Dounia Skalli and the team at centre hospitalier intercommunal de Créteil, France for enrolling the 500th patient to the SHAPE study! On behalf of the SHAPE trial committee, we would like to thank you for your tremendous and unwavering support of our trial.
The Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has a job opening for a Safety Desk Team Leader
This Friday is the CCTG 2018 Annual Spring Meeting of Participants
The Canadian Cancer Trials Group Annual Spring Meeting of Participants represents a major gathering of the Canadian oncology community where trials that cover the spectrum of cancer treatment are designed and reviewed. Traditionally, the meeting includes discussions of trials that are in development, under conduct or have results to be shared.
Online registration has closed and on site registration will open Friday April 27 at the Chelsea Hotel.
Ovarian Cancer Canada asks us to urge the government to fund ovarian cancer research in Canada
NEC 2 ( NCT01229943) Randomized Phase II Study of Everolimus Alone versus Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours has been permanently closed by the lead group.
About the trial
The official CCTG Facebook page is here!
With so many of our partners and collaborators already using this social media platform, CCTG has officially joined the Cancer Clinical Trials conversation on Facebook. The group's new social media page will focus on sharing lay related stories and information on the subject of cancer clinical trials. With emerging treatments and clinical practice changes it is a great way to keep everyone up-to-date with the latest information in the ever changing world of cancer research.
